This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
4-FA: Difference between revisions
>FreDi mNo edit summary |
>Myriadis m Added citation to legal status in France + changed wording |
||
| (46 intermediate revisions by 8 users not shown) | |||
| Line 2: | Line 2: | ||
{{SubstanceBox/4-FA}} | {{SubstanceBox/4-FA}} | ||
'''4-Fluoroamphetamine''' (also known as '''4-FA''', '''4-FMP''', '''para-Fluoroamphetamine''', '''PAL-303''' and colloquially as '''Flux''') is a novel synthetic [[chemical class::amphetamine| | '''4-Fluoroamphetamine''' (also known as '''4-FA''', '''4-FMP''', '''para-Fluoroamphetamine''', '''PAL-303''' and colloquially as '''Flux''') is a novel synthetic [[chemical class::Substituted amphetamine|amphetamine]] compound that produces a unique progressive mixture of [[psychoactive class::entactogen|entactogenic]] and [[psychoactive class::stimulant]] effects when [[Routes of administration|administered]]. It is part of a series of fluorinated amphetamine analog that initially included such compounds as [[2-FA]], [[2-FMA]], and [[3-FA]].<ref name="Rosner2005">{{cite journal | vauthors=((Rösner, P.)), ((Quednow, B.)), ((Girreser, U.)), ((Junge, T.)) | journal=Forensic Science International | title=Isomeric Fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs) | volume=148 | issue=2–3 | pages=143–156 | date= March 2005 | url=https://linkinghub.elsevier.com/retrieve/pii/S0379073804003251 | issn=03790738 | doi=10.1016/j.forsciint.2004.05.003}}</ref> | ||
Anecdotal reports have described the subjective effects of [[4-FA]] as having a moderate [[MDMA|MDMA-like]] [[entactogenic]] onset for the initial few hours of the experience that then gradually transitions into traditional [[amphetamine|amphetamine-type]] [[stimulation]] (for a total duration of around 6 to 8 hours) with residual effects that can last a few hours afterward.{{citation needed}} | Anecdotal reports have described the subjective effects of [[4-FA]] as having a moderate [[MDMA|MDMA-like]] [[entactogenic]] onset for the initial few hours of the experience that then gradually transitions into traditional [[amphetamine|amphetamine-type]] [[stimulation]] (for a total duration of around 6 to 8 hours) with residual effects that can last a few hours afterward.{{citation needed}} | ||
4-FA is rarely found on the streets but was commonly sold as a grey area [[research chemical]] by online vendors along with related compounds such as [[2-FMA]] and [[3-FA]].<ref>The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | 4-FA is rarely found on the streets but was commonly sold as a grey area [[research chemical]] by online vendors along with related compounds such as [[2-FMA]] and [[3-FA]].<ref name="Nagai2007">{{cite journal | vauthors=((Nagai, F.)), ((Nonaka, R.)), ((Satoh Hisashi Kamimura, K.)) | journal=European Journal of Pharmacology | title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | volume=559 | issue=2–3 | pages=132–137 | date=22 March 2007 | issn=0014-2999 | doi=10.1016/j.ejphar.2006.11.075}} | ||
</ref><ref name="Rosner2005"/> Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-FA, and it has only a brief history of human usage. Due to its strong psychostimulant effects, likely habit-forming properties as well as poorly understood toxicity profile, it is strongly recommended that one use proper [[harm reduction]] practices if choosing to use this substance. | |||
==Chemistry== | ==Chemistry== | ||
4-Fluoroamphetamine (4-FA) is a synthetic molecule of the [[amphetamine]] family. Molecules of the amphetamine class contain a [[phenethylamine]] core featuring a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain with an additional methyl substitution at R<sub>α</sub>. Amphetamines are alpha-methylated phenethylamines. 4-fluoroamphetamine contains a fluorine atom at R<sub>4</sub> of its phenyl ring and is a fluorinated analogue of amphetamine. | 4-Fluoroamphetamine (4-FA) is a synthetic molecule of the [[Substituted amphetamine|amphetamine]] family. Molecules of the amphetamine class contain a [[phenethylamine]] core featuring a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain with an additional methyl substitution at R<sub>α</sub>. Amphetamines are alpha-methylated phenethylamines. 4-fluoroamphetamine contains a fluorine atom at R<sub>4</sub> of its phenyl ring and is a fluorinated analogue of amphetamine. | ||
[[File:samphetamine.png|thumb|right|240px|thumb|right||Substitutive structure of an amphetamine molecule]] | [[File:samphetamine.png|thumb|right|240px|thumb|right||Substitutive structure of an amphetamine molecule]] | ||
==Pharmacology== | ==Pharmacology== | ||
4-Fluoroamphetamine acts as a releasing agent and reuptake inhibitor of dopamine, serotonin, and norepinephrine producing stimulating amphetamine-like effects at lower doses and euphoric, entactogenic effects similar to MDMA at dosages above 100mg. The mechanism of action of 4-FA effectively boosts the levels of the norepinephrine, dopamine, and serotonin [[neurotransmitters]] in higher doses in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine, norepinephrine, and serotonin to accumulate within the brain, resulting in stimulating, euphoric and [[entactogen]]ic effects.<ref> | 4-Fluoroamphetamine acts as a releasing agent and reuptake inhibitor of dopamine, serotonin, and norepinephrine producing stimulating amphetamine-like effects at lower doses and euphoric, entactogenic effects similar to MDMA at dosages above 100mg. The mechanism of action of 4-FA effectively boosts the levels of the norepinephrine, dopamine, and serotonin [[neurotransmitters]] in higher doses in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine, norepinephrine, and serotonin to accumulate within the brain, resulting in stimulating, euphoric and [[entactogen]]ic effects.<ref>{{cite journal | vauthors=((Fuller, R. W.)), ((Baker, J. C.)), ((Perry, K. W.)), ((Molloy, B. B.)) | journal=Neuropharmacology | title=Comparison of 4-chloro-, 4-bromo- and 4-fluoroamphetamine in rats: Drug levels in brain and effects on brain serotonin metabolism | volume=14 | issue=10 | pages=739–746 | date=1 October 1975 | url=https://www.sciencedirect.com/science/article/pii/0028390875900994 | issn=0028-3908 | doi=10.1016/0028-3908(75)90099-4}}</ref><ref name="Nagai2007"/> | ||
==Subjective effects== | ==Subjective effects== | ||
It is commonly reported that the first three to four hours of 4-FA present distinct [[ | It is commonly reported that the first three to four hours of 4-FA present distinct [[entactogenic]] effects that have been reported as feeling somewhat similar to MDMA although not quite as powerful. This is thought to correlate with the duration in which it is promoting the release of [[serotonin]] (in addition to [[dopamine]] and [[norepinephrine]]). After this first phase of the experience, the effect then shifts towards something which feels like classic [[amphetamine]] stimulation which can persist for an extended period.{{citation needed}} | ||
'''Do not use 4-FA if you have a history of heart-related issues or experience a severe headache after its use.''' We have been made aware of a report released by Trimbos-instituut<ref>https://www.trimbos.nl/</ref> and Nationaal Vergiftigingen Informatie Centrum<ref>https://www.vergiftigingen.info | '''Do not use 4-FA if you have a history of heart-related issues or experience a severe headache after its use.''' We have been made aware of a report released by Trimbos-instituut<ref>{{Citation | title=Voor mentale gezondheid | url=https://www.trimbos.nl/}}</ref> and Nationaal Vergiftigingen Informatie Centrum<ref>{{Citation | title=Vergiftigingen.info - Home | url=https://www.vergiftigingen.info}}</ref> (NVIC), describing incidents of strokes after an increased use of 4-FA. In addition to the common amphetamine-like effects (agitation, anxiety, tachycardia, hypertension, chest pain et al.), serious cardio- and cerebrovascular complications have been reported, including rhythm (sinus arrhythmia, ventricular extrasystoles (bigeminy), conduction disturbances) and acute cardiac failure. Although a causal relationship has not been confirmed, when presented with a severe headache and lateralization after 4-FA usage, a medical evaluation at an emergency department should be conducted immediately. <ref>https://psychonautwiki.org/wiki/File:Behandeling-4-fa-intoxicatie.pdf</ref> | ||
{{Preamble/SubjectiveEffects}} | {{Preamble/SubjectiveEffects}} | ||
| Line 46: | Line 47: | ||
*'''[[Effect::Orgasm suppression]]''' | *'''[[Effect::Orgasm suppression]]''' | ||
*'''[[Effect::Temporary erectile dysfunction]]''' | *'''[[Effect::Temporary erectile dysfunction]]''' | ||
*'''[[Effect::Difficulty urinating]]''' | |||
*'''[[Effect::Teeth grinding]]''' | *'''[[Effect::Teeth grinding]]''' | ||
*'''[[Effect::Seizure]]''' - This is a rare effect but is thought to be able to occur in those predisposed to them, especially when taking heavier-than-recommended doses or redosing while in physically taxing conditions such as being dehydrated, fatigued, undernourished, or overheated.{{citation needed}} | *'''[[Effect::Seizure]]''' - This is a rare effect but is thought to be able to occur in those predisposed to them, especially when taking heavier-than-recommended doses or redosing while in physically taxing conditions such as being dehydrated, fatigued, undernourished, or overheated.{{citation needed}} | ||
| Line 67: | Line 69: | ||
*'''[[Effect::Anxiety suppression]]''' | *'''[[Effect::Anxiety suppression]]''' | ||
*'''[[Effect::Disinhibition]]''' | *'''[[Effect::Disinhibition]]''' | ||
*'''[[Effect::Empathy, affection, and sociability enhancement]]''' - In comparison to other substances, this effect can be described as identical to the effects produced by [[MDMA]], but with less intensity. | *'''[[Effect::Empathy, affection, and sociability enhancement]]''' - In comparison to other substances, this effect can be described as identical to the effects produced by [[MDMA]], but with less intensity. Like '''[[Effect::Cognitive euphoria|euphoria]]''', it is most present at dosages above 100mg. | ||
*'''[[Effect::Cognitive euphoria]]''' - This effect can be described in its manifestation as a series of euphoric waves that recede and reappear randomly throughout the experience. It is most present at dosages above 100mg. | *'''[[Effect::Cognitive euphoria]]''' - This effect can be described in its manifestation as a series of euphoric waves that recede and reappear randomly throughout the experience. It is most present at dosages above 100mg. | ||
*'''[[Effect::Thought acceleration]]''' | *'''[[Effect::Thought acceleration]]''' | ||
| Line 97: | Line 99: | ||
*'''[[Effect::Cognitive fatigue]]''' | *'''[[Effect::Cognitive fatigue]]''' | ||
*'''[[Effect::Depression]]''' | *'''[[Effect::Depression]]''' | ||
*'''[[Sleep paralysis]]''' - Some users report a higher incidence of experiencing sleep paralysis after consuming 4-FA, usually only at higher doses. | *'''[[Effect::Sleep paralysis]]''' - Some users report a higher incidence of experiencing sleep paralysis after consuming 4-FA, usually only at higher doses. | ||
*'''[[Effect::Irritability]]''' | *'''[[Effect::Irritability]]''' | ||
*'''[[Effect::Motivation suppression]]''' | *'''[[Effect::Motivation suppression]]''' | ||
| Line 111: | Line 113: | ||
{{#ask: [[Category:4-FA]][[Category:Experience]]|format=ul|Columns=1}} | {{#ask: [[Category:4-FA]][[Category:Experience]]|format=ul|Columns=1}} | ||
Additional experience reports can be found here: | Additional experience reports can be found here: | ||
* [https://www.erowid.org/experiences/subs/exp_4Fluoroamphetamine.shtml Erowid Experience Vaults: 4-FA] | |||
*[https://www.erowid.org/experiences/subs/exp_4Fluoroamphetamine.shtml Erowid Experience Vaults: 4-FA] | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
| Line 118: | Line 119: | ||
The toxicity and long-term effects of recreational 4-FA use have only scarcely been studied because 4-FA has very little history of human usage. Anecdotal evidence, as well as several case reports, suggest there is a small to moderate individual health risk associated with the use of 4-FA. Among these, it appears there is an especially a high risk for acute cardiovascular toxicity. Some people in the Netherlands, only using a moderate dose, have died due to cardiac arrest or suffered severe brain damage due to a stroke. The mechanism of this acute toxicity is not yet known, but it seems as though the stroke starts off as an intense headache or even a migraine attack, that slowly worsens.<ref>https://psychonautwiki.org/wiki/File:4-FA%20risicobeoordeling%20(2016).pdf</ref> | The toxicity and long-term effects of recreational 4-FA use have only scarcely been studied because 4-FA has very little history of human usage. Anecdotal evidence, as well as several case reports, suggest there is a small to moderate individual health risk associated with the use of 4-FA. Among these, it appears there is an especially a high risk for acute cardiovascular toxicity. Some people in the Netherlands, only using a moderate dose, have died due to cardiac arrest or suffered severe brain damage due to a stroke. The mechanism of this acute toxicity is not yet known, but it seems as though the stroke starts off as an intense headache or even a migraine attack, that slowly worsens.<ref>https://psychonautwiki.org/wiki/File:4-FA%20risicobeoordeling%20(2016).pdf</ref> | ||
The [[LD50|LD<sub>50</sub>]] (mouse; i.p.) of 4-FA is 46 mg/kg.<ref>E. | The [[LD50|LD<sub>50</sub>]] (mouse; i.p.) of 4-FA is 46 mg/kg.<ref>{{cite journal | vauthors=((Costa, E.)), ((Garattini, S.)) | veditors=((Domino, E. F.)) | journal=Electroencephalography and Clinical Neurophysiology | title=Amphetamines and related compounds | volume=30 | issue=6 | pages=579 | date= June 1971 | url=https://linkinghub.elsevier.com/retrieve/pii/001346947190160X | issn=00134694 | doi=10.1016/0013-4694(71)90160-X}}</ref> 4-FA does not cause long-lasting depletion of brain [[serotonin]] unlike [[MDMA]] or [[4-FA]]'s analogs [https://en.wikipedia.org/wiki/Para-Chloroamphetamine 4-CA] and [https://en.wikipedia.org/wiki/Para-Bromoamphetamine 4-BA]. | ||
It is also worth noting that 4-FA is particularly caustic in comparison to other compounds and can, therefore, cause chemical burns within the nasal passage and throat if it is [[insufflated]]. This method of administration is discouraged. | It is also worth noting that 4-FA is particularly caustic in comparison to other compounds and can, therefore, cause chemical burns within the nasal passage and throat if it is [[insufflated]]. This method of administration is discouraged. | ||
| Line 125: | Line 126: | ||
===Tolerance and addiction potential=== | ===Tolerance and addiction potential=== | ||
As with other [[ | As with other [[stimulants]], the chronic use of 4-FA can be considered [[Addiction potential::moderately addictive with a high potential for abuse]] and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage. | ||
Tolerance to many of the effects of 4-FA [[Time to full tolerance::develops with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). This is how long it takes to reduce the tolerance for the stimulating effects. Tolerance for the [[Empathy, love, and sociability enhancement|entactogenic effects]] may take a longer period to reduce. 4-FA presents cross-tolerance with [[Cross-tolerance::all [[dopamine]]rgic [[ | Tolerance to many of the effects of 4-FA [[Time to full tolerance::develops with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). This is how long it takes to reduce the tolerance for the stimulating effects. Tolerance for the [[Empathy, love, and sociability enhancement|entactogenic effects]] may take a longer period to reduce. 4-FA presents cross-tolerance with [[Cross-tolerance::all [[dopamine]]rgic [[stimulants]]]], meaning that after the consumption of 4-FA all [[stimulants]] will have a reduced effect. | ||
===Psychosis=== | ===Psychosis=== | ||
{{Main|Stimulant psychosis}} | {{Main|Stimulant psychosis}} | ||
4-FA, like other stimulants, can result in a stimulant psychosis that may present with a variety of symptoms (e.g., [[paranoia]], [[External hallucinations|hallucinations]], or [[delusions]]).<ref> | 4-FA, like other stimulants, can result in a stimulant psychosis that may present with a variety of symptoms (e.g., [[paranoia]], [[External hallucinations|hallucinations]], or [[delusions]]).<ref>{{Citation | vauthors=((National Institute on Drug Abuse)) | title=Emerging Trends | url=https://nida.nih.gov/research-topics/emerging-trends-alerts}}</ref><ref name="amppsychosis">{{cite journal | vauthors=((Shoptaw, S. J.)), ((Kao, U.)), ((Ling, W.)) | veditors=((Cochrane Drugs and Alcohol Group)) | journal=Cochrane Database of Systematic Reviews | title=Treatment for amphetamine psychosis | date=21 January 2009 | url=https://doi.wiley.com/10.1002/14651858.CD003026.pub3 | issn=14651858 | doi=10.1002/14651858.CD003026.pub3}}</ref> A review on treatment for amphetamine, [[amphetamine|dextroamphetamine]], and [[methamphetamine]] abuse-induced psychosis states that about 5–15% of users fail to recover completely.<ref name="amppsychosis" /><ref>{{cite book | vauthors=((Hofmann, F. G.)) | date= 1983 | title=A handbook on drug and alcohol abuse: the biomedical aspects | publisher=Oxford University Press | edition=2nd ed | isbn=9780195030563}}</ref> The same review asserts that, based upon at least one trial, [[antipsychotic]] medications effectively resolve the symptoms of acute amphetamine psychosis.<ref name="amppsychosis" /> | ||
===Dangerous interactions=== | ===Dangerous interactions=== | ||
| Line 138: | Line 139: | ||
==Legal status== | ==Legal status== | ||
*'''Austria''': 4-FA is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).{{citation needed}} | |||
*'''Austria | *'''Brazil''': 4-FA is illegal to possess, produce and sell as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref> | ||
*'''Brazil | *'''Canada''': 4-FA would fall under Schedule I as it is considered an analog of amphetamine.<ref>{{Citation | vauthors=((Branch, L. S.)) | year=2022 | title=Consolidated federal laws of Canada, Controlled Drugs and Substances Act | url=https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html}}</ref> | ||
*'''Canada | *'''France''': 4-FA is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.<ref>{{Citation | title=Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants | url=https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2020-11-20/}}</ref> | ||
*'''France | *'''Germany''': 4-FA is controlled under Anlage I BtMG (''Narcotics Act, Schedule I'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Anlage I BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref> as of July 26, 2012.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F*%5B%40attr_id%3D%27bgbl112s1639.pdf%27%5D|title=Sechsundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|access-date=December 18, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref> | ||
*'''Germany | *'''Hungary''': In January 2012, 4-FA became controlled in Hungary.{{citation needed}} | ||
*'''Hungary | *'''Israel''': In December 2007, 4-FA was added to Israel's list of controlled substances, making it illegal to buy, sell, or possess.{{citation needed}} | ||
*'''Israel | *'''The Netherlands''': 4-FA is a Schedule 1 drug in the Netherlands as of May 25th 2017. <ref>https://www.rijksoverheid.nl/actueel/nieuws/2017/05/24/verbod-op-drug-4-fluoramfetamine-gaat-vrijdag-25-mei-in</ref> | ||
*'''The Netherlands | *'''New Zealand''': 4-FA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.<ref>{{Citation | title=Misuse of Drugs Act 1975 No 116 (as at 01 July 2022), Public Act – New Zealand Legislation | url=https://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html}}</ref> | ||
*'''New Zealand | *'''Poland''': 4-FA is controlled in Poland.{{citation needed}} | ||
*'''Poland | *'''Slovak Republic''': Beginning March 1, 2011, 4-Fluoroamphetamine is controlled in the Slovak Republic.{{citation needed}} | ||
*'''Slovak Republic | *'''Switzerland''': 4-FA is a controlled substance specifically named under Verzeichnis D.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | ||
*'''United Kingdom | *'''Turkey:''' 4-FA is a classed as drug and is illegal to possess, produce, supply, or import.<ref name="Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742">{{Citation | title=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü | url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm}}</ref> <ref name="List of illegal substances for law"> https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf</ref> | ||
*'''United States | *'''United Kingdom''': 4-FA is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.<ref>{{Citation | title=Misuse of Drugs Act 1971 | url=https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I}}</ref> | ||
**'''Arizona | *'''United States''': 4-FA is not scheduled on a federal level in the United States.{{citation needed}} | ||
**'''Louisiana | **'''Arizona''': 4-FA was added to the "Dangerous Drug" list in April 2014.{{citation needed}} | ||
**'''Virginia | **'''Louisiana''': 4-FA is currently listed as a Schedule I drug as of June 2013.{{citation needed}} | ||
**'''Virginia''': 4-FA is classified as a Schedule I drug.{{citation needed}} | |||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Research chemical]] | *[[Research chemical]] | ||
| Line 167: | Line 168: | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/4-Fluoroamphetamine 4-FA (Wikipedia)] | *[https://en.wikipedia.org/wiki/4-Fluoroamphetamine 4-FA (Wikipedia)] | ||
*[https://erowid.org/chemicals/4_fluoroamphetamine/4_fluoroamphetamine.shtml 4-FA (Erowid Vault)] | *[https://erowid.org/chemicals/4_fluoroamphetamine/4_fluoroamphetamine.shtml 4-FA (Erowid Vault)] | ||
| Line 173: | Line 173: | ||
===Discussion=== | ===Discussion=== | ||
*[http://www.bluelight.org/vb/threads/498590-Big-n-Dandy-4-FA-(4-fluoroamphetamine)-thread-v-1-0 Big n Dandy 4-FA (4-fluoroamphetamine) thread v.1.0 (Bluelight)] | *[http://www.bluelight.org/vb/threads/498590-Big-n-Dandy-4-FA-(4-fluoroamphetamine)-thread-v-1-0 Big n Dandy 4-FA (4-fluoroamphetamine) thread v.1.0 (Bluelight)] | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Psychoactive substance]] | [[Category:Psychoactive substance]] | ||
[[Category:Stimulant]] | [[Category:Stimulant]] | ||
[[Category:Entactogen]] | [[Category:Entactogen]] | ||
[[Category:Amphetamine]] | [[Category:Amphetamine]] | ||
[[Category:Research chemical]] | |||
{{#set:Featured=true}} | {{#set:Featured=true}} | ||